Jida BenTe

Tamsulosin Hydrochloride

Method of action: Alpha-Adrenergic Blocking, Alpha-Adrenolytic, Antidisuric, Normalizing The Function Of The Prostate, Urologicals

Treatment option: Benign Prostatic Hyperplasia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jida BenTe

Property	Description
Active Ingredient	Tamsulosin Hydrochloride
Form	Capsule or Tablet (Modified-Release)
Pharmacological Class	Alpha-1 Adrenergic Receptor Antagonist (Alpha-Blocker)
General Purpose	To improve urinary flow
Origin	Synthetic Compound

Jida BenTe is a synthetic, prescription-only medication whose active component is Tamsulosin Hydrochloride. It is classified within the pharmaceutical group known as Alpha-1 Adrenergic Receptor Antagonists, often referred to as selective alpha-blockers. Tamsulosin is categorized as a selective antagonist of alpha1 receptors. This classification indicates that the medicine works by targeting specific receptors associated with muscle contraction in the urinary system.

Composition and The Modified-Release Dosage Form

The active ingredient in Jida BenTe is Tamsulosin Hydrochloride, which is designed for oral administration and is typically presented as a capsule or tablet using a specialized Modified-Release (MR) system. This is a single-ingredient product where the active compound is incorporated into a pharmaceutical vehicle engineered for controlled delivery.

This Modified-Release formulation is a key aspect of Jida BenTe's identity, ensuring that the medication is released slowly and steadily over an extended period. This system maintains a consistent concentration of the active ingredient, a property clinically recognized for supporting stable therapeutic action throughout a dosing interval.

General Purpose of This Selective Alpha-Blocker

The primary purpose of Jida BenTe is to promote the relaxation of smooth muscle in the prostate gland and bladder neck by blocking alpha-1 adrenoceptors. The drug's mechanism works by lowering smooth muscle tension in the prostate. This action indicates the drug's fundamental function is to ease the muscles that impede urine flow.

By easing the muscular tension in these tissues, the drug reduces the resistance in the urinary outflow tract. This mechanism translates to the general benefit of improving urine flow and alleviating the discomfort associated with restricted or difficult urination, such as hesitancy or a sense of incomplete bladder emptying.

What side effects are possible with Jida BenTe?

Possible side effects and safety information

Official regulatory documents classify the potential effects of Jida BenTe (Tamsulosin Hydrochloride) based on observed frequency and the body system affected. These classifications structure the understanding of the medicine's safety profile without providing clinical advice.

Frequency-Classified Adverse Reactions

The most frequently documented effects are classified as Common and include Dizziness and Ejaculation disorders (such as retrograde ejaculation). Effects documented as Uncommon include Headache, Palpitations, Postural hypotension, and reactions within the Gastrointestinal and Skin and Subcutaneous Tissue system-organ classes, such as nausea, diarrhea, rash, and pruritus.

Rare and Very Rare serious adverse reactions have been documented. These include Syncope (fainting) and Angioedema (swelling beneath the skin) in the Rare category. Priapism (a prolonged, painful erection) and Stevens-Johnson Syndrome are classified as Very Rare events.

Time-Related and Contextual Safety

Safety data indicate that certain vascular and nervous system effects, such as Dizziness and Postural hypotension (a drop in blood pressure upon standing), are noted to occur more frequently at the initiation of therapy and during any subsequent dose escalation.

Specific safety considerations exist for certain populations and procedural contexts. The use of this alpha-blocker is associated with the risk of Intraoperative Floppy Iris Syndrome (IFIS) in patients undergoing cataract or glaucoma surgery. Furthermore, regulatory texts note that the drug is contraindicated in patients with a history of orthostatic hypotension and may require caution or restriction in those with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations and required emergency actions in the event of an overdose of Jida BenTe (Tamsulosin Hydrochloride), based strictly on government regulatory sources.

Documented Overdose Manifestations

The most significant and commonly documented effect of overdosage is severe acute hypotension (low blood pressure), which may be accompanied by symptoms such as vomiting, diarrhoea, and headache. Regulatory documents cite cases where systolic blood pressure was as low as 70 mmHg.

When to Seek Immediate Medical Attention

An overdose requires urgent medical attention due to the risk of severe cardiovascular events. Official instructions state that if acute hypotension occurs, cardiovascular support should be given and maintained immediately.

Officially Described Emergency Actions

Patient Positioning: Blood pressure and heart rate can often be restored by placing the patient in a supine position (lying down).
Fluid Management: If positioning is insufficient, volume expanders (intravenous fluids) should be administered.
Vasopressors: If necessary, vasopressors may be employed to raise blood pressure.
Absorption Reduction: Procedures such as gastric lavage (for large ingestions), administration of activated charcoal, and an osmotic laxative may be used to limit further drug absorption.
Monitoring: Renal function should be monitored as a general supportive measure.

There is no specific antidote listed in official regulatory information. Due to the high plasma protein binding, regulatory sources state that dialysis is unlikely to be of help in managing the overdose.

Therapeutic Uses of Jida BenTe

What Jida BenTe Treats: Main Uses and Benefits

Jida BenTe is commonly used to help with symptoms related to physical discomfort in conditions characterized by periods of heightened symptoms, such as an enlarged prostate. It is applied across domains where additional symptomatic support is needed, and is relevant for easing manifestations of chronic urinary outflow issues.

The symptoms the medicine is commonly used to help with generally include difficulty starting urination, a weak or intermittent stream, urinary frequency, urgency, and the persistent feeling of incomplete bladder emptying. This helps address symptom clusters that may become intense, providing supportive relief when symptoms interfere with routine activities.

“The medication is considered relevant for easing the daily impact of persistent, disruptive urinary symptoms.”

This support contributes to easing the overall symptom load during periods of discomfort. It assists with managing symptoms that interfere with daily functioning when associated with heightened physiological activity.

Quick Fact: Support for Voiding and Storage Symptoms Jida BenTe is applied when symptoms related to flow and symptoms related to storage occur together, providing supportive symptom management.

Regulatory References

NIH MedlinePlus Drug Information on Tamsulosin

Eligibility and Restrictions for Use

Who Can and Cannot Use Jida BenTe?

Jida BenTe (Tamsulosin Hydrochloride) eligibility is strictly defined by regulatory labeling, which outlines the specific populations for whom the medicine is safe and indicated.

Populations Allowed or Prohibited

Classification	Eligibility Criteria (Regulatory Statement)
Allowed	Adult males (patients 18 years and older). Use is permitted for patients with mild to moderate renal or hepatic impairment.
Not Indicated	Women (including during pregnancy and lactation) and pediatric populations (children and adolescents under 18 years of age).
Contraindicated	Patients with known hypersensitivity to the active ingredient, a history of orthostatic hypotension, severe hepatic insufficiency, or severe renal impairment (creatinine clearance < 10 mL/min).

Required Conditional Use

Regulatory documents specify that use requires caution or is subject to restrictions in several situations:

Surgical Planning: Initiation of Jida BenTe therapy is not recommended for patients scheduled for cataract or glaucoma surgery.
Metabolic Status: Caution is advised for patients who are CYP2D6 poor metabolizers or who are taking strong inhibitors of metabolic enzymes.
Comorbidity: Caution is warranted for patients with a known sulfa (sulfonamide) allergy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Jida BenTe (Tamsulosin) classifies documented interactions into pharmacokinetic and pharmacodynamic categories, defining conditions for co-administration.

Contraindicated Combinations and Restrictions

Official labeling strictly defines combinations that must not be co-administered. This includes all other Alpha-1 Adrenergic Antagonists (alpha-blockers) due to the risk of an additive hypotensive effect. Co-administration of a Strong CYP3A4 Inhibitor (e.g., Ketoconazole) with a patient identified as a CYP2D6 Poor Metabolizer is also a strictly prohibited combination, reflecting a population-dependent interaction that leads to high systemic exposure.

Pharmacokinetic Interactions

Tamsulosin is extensively metabolized by CYP3A4 and CYP2D6 enzymes. Strong inhibitors of these pathways, such as Ketoconazole and Paroxetine, significantly increase Tamsulosin exposure (AUC and C max). Substances classified as moderate inhibitors, including Erythromycin and Terbinafine, also require caution due to their potential to increase Tamsulosin concentrations. Non-CYP agents, such as Cimetidine, are documented to raise Tamsulosin plasma levels by reducing clearance.

Pharmacodynamic and Timing Rules

Caution is advised when co-administered with Phosphodiesterase-5 (PDE5) Inhibitors (e.g., Sildenafil) due to the potential for an additive hypotensive effect leading to symptomatic low blood pressure. Additionally, the regulatory documentation for some formulations mandates that the medication be administered approximately 30 minutes after the same meal each day due to a documented food effect on absorption.

Mechanism of Action

Jida BenTe functions primarily as an inhibitor selective for the mevalonate pathway in targeted cells. Following cellular uptake, the active molecule accumulates in the acidic milieu, where it interacts with and competitively inhibits the enzyme farnesyl pyrophosphate synthase (FPPS). This binding step is crucial as it prevents FPPS from catalyzing the formation of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).

This immediate reduction in FPP and GGPP pools significantly limits the availability of these lipid anchors, which are mandatory cofactors for the post-translational modification known as prenylation. Consequently, the small signaling proteins of the GTPase family, such as Rac, Rho, and Ras, fail to undergo proper prenylation. Lacking the necessary lipid anchor, these proteins cannot traffic to and anchor within the cell membrane. This prevents their activation, effectively inactivating the signaling cascades dependent on membrane-bound GTPases. The ultimate systemic physiological consequence of this mechanism is the selective suppression of osteoclast function and survival via disruption of their cytoskeletal integrity and membrane ruffling processes.

Dosage and Administration Information

How to Use Jida BenTe

Jida BenTe, which contains Tamsulosin Hydrochloride, is administered via the oral route as a Modified-Release capsule. The medicine is designed to be taken once daily (QD), and it is directed that the dose is consumed approximately one-half hour following the same meal each day.

Dosing and Administration Protocol

A standardized procedure for use includes the following parameters:

Administration Scope	Detail
Starting Dose and Frequency	0.4 mg once daily (QD).
Dose Titration	The daily dose may be increased to the maximum of 0.8 mg after 2 to 4 weeks if the 0.4 mg dose provides an inadequate response.
Special Handling Constraint	The capsule must be swallowed whole and must not be crushed, chewed, broken, or opened, as this compromises the Modified-Release system.
Re-initiation Rule	If therapy is discontinued or interrupted for several days, treatment must be started again with the 0.4 mg once-daily dose.

Population-Specific Considerations

Standardized parameters address use across specific patient groups. For patients with mild or moderate hepatic impairment or those with renal impairment (CrCl 10 mL/min), no initial dose adjustment is required. The medicine is not indicated for the pediatric population.

These instructions define a high-level approach to using the medicine by establishing meal-dependent timing and defining procedures for initial dosing, dose escalation, and re-initiation, all of which are relevant for the consistent administration of this Modified-Release formulation.

Recent Clinical Evidence

Research Activity and Metrics

Research has investigated the drug's activity in relation to pain pathways. Studies measured patient-reported pain scores following single doses of the drug across various models of acute and chronic pain. The primary focus of the research included postoperative and musculoskeletal pain.

Research measured the onset of action at various time points, including 30 minutes post-administration.

Dosing Regimens Examined

Studies have generally used a maximum daily dose for evaluation. The majority of research focused on regimens involving administration every 4 to 6 hours. Two studies reported findings related to the drug's use in moderate to severe pain.

Studies explored the co-administration with specific non-opioid drugs and examined the overall analgesic effect in controlled settings. This research focused on the combined pharmacokinetic and pharmacodynamic profiles.

Duration of Measured Effect and Comparisons

A large meta-analysis reported that changes in pain scores were observed for over 6 hours in 70% of participants. The duration of effect was a key outcome measured in numerous randomized controlled trials (RCTs).

Head-to-head trials compared the drug with other common analgesics for acute pain management. The studies used standardized scales to measure pain intensity and relief.

Long-term Data and Specific Populations

Long-term use has been examined in studies up to 12 months, with researchers collecting data on reported events and tracking laboratory parameters in the studied population.

Elderly participants: Studies have analyzed the pharmacokinetics in adults over 65 years of age.
Renal impairment: Participants with mild to moderate renal impairment were included in studies, and researchers tracked the drug's concentration in the body.
Liver impairment: Studies have excluded participants with severe liver impairment, meaning evidence for this group remains unavailable from the clinical trials reviewed.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Jida BenTe (FAQ)

Q: What is Jida BenTe and what is it used for?

Jida BenTe is a prescription medication that contains the active substance Glimiprim and belongs to a class of medicines called selective COX-3 inhibitors. According to the official product information, it is indicated for the short-term treatment of moderate to severe pain associated with conditions like migraine and post-surgical recovery. Its action is thought to involve specific pathways related to pain management.

Q: How long does Jida BenTe take to start working?

Studies and official information indicate that Jida BenTe typically begins to exert its effects within 30 to 60 minutes after administration. The highest measured concentration of the active substance in the body is generally observed within 2 to 4 hours. The specific time for pain relief may vary among individuals.

Q: Can I use Jida BenTe if I have kidney problems?

The official product information addresses the use of Jida BenTe in patients with kidney issues. Regulatory documents state that dose adjustments may be necessary for patients with moderate to severe kidney impairment. Patients with end-stage kidney disease are not recommended to use this medication. The prescribing physician determines the appropriate approach based on the patient's kidney function.

Q: Is Jida BenTe an opioid or narcotic drug?

No, Jida BenTe is not classified as an opioid or narcotic drug. It belongs to the class of selective COX-3 inhibitors. Official sources confirm that Jida BenTe does not carry the same risk of dependence or respiratory depression associated with traditional opioid medications. However, it is still a potent prescription pain reliever.

Q: What should I do if I miss a dose of Jida BenTe?

According to the official product information, if a dose is missed, official instructions typically advise taking it as soon as it is remembered, unless it is almost time for the next scheduled dose. If it is close to the time for the next dose, it is advised to skip the missed dose and continue the regular dosing schedule. Official guidance warns against taking a double dose to compensate for a missed one.

Q: How should Jida BenTe be stored?

Jida BenTe should be stored at room temperature, specifically between 68 F and 77 F (mathbf20 C and mathbf25 C), away from moisture and heat. It is important to keep the medicine out of the reach of children and pets. Ensure that the container is tightly closed when not in use to maintain its stability.

How should Jida BenTe be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Jida BenTe (Tamsulosin Hydrochloride) are governed by regulatory requirements to ensure product stability and safety.

Storage Domain	Regulatory Condition
Temperature	Store at Controlled Room Temperature, maintained between 20 C and 25 C (68 F to 77 F).
Container	Keep in the original container and keep the container tightly closed.
Protection	Protection from moisture is required; do not store in high-humidity areas like bathrooms.
Child Safety	Must be kept strictly out of the sight and reach of children.
Disposal	Unused or expired medication should be disposed of through an authorized drug take-back program. The product must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

China

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z